{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:35Z","timestamp":1786987535577,"version":"build-2736575974"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104953","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T23:09:56Z","timestamp":1758064196000},"page":"104953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Decoding optic pathway gliomas: Molecular insights and emerging therapies"],"prefix":"10.1016","volume":"216","author":[{"given":"Jing","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shepeng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104953_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11060-019-03264-2","article-title":"Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma","volume":"144","author":"Acharya","year":"2019","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/WNL.38.7.1071","article-title":"Treatment response in malignant optic glioma of adulthood","volume":"38","author":"Albers","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2025.104953_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3171\/jns.1988.68.1.0085","article-title":"Gliomas of the optic nerve or chiasm. Outcome by patients' age, tumor site, and treatment","volume":"68","author":"Alvord","year":"1988","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3928\/0191-3913-19950901-07","article-title":"Prevalence of intracranial lesions in children initially diagnosed with disconjugate nystagmus (spasmus nutans)","volume":"32","author":"Arnoldi","year":"1995","journal-title":"J. Pedia Ophthalmol. Strabismus"},{"key":"10.1016\/j.critrevonc.2025.104953_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1227\/00006123-198212000-00011","article-title":"Malignant optic glioma presenting radiologically as a \"cystic\" suprasellar mass: case report and review of the literature","volume":"11","author":"Barbaro","year":"1982","journal-title":"Neurosurgery"},{"key":"10.1016\/j.critrevonc.2025.104953_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00307925","article-title":"Our treatment philosophy of gliomas of the anterior visual pathways","volume":"6","author":"Benes","year":"1990","journal-title":"Childs Nerv. Syst."},{"key":"10.1016\/j.critrevonc.2025.104953_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/brain\/105.1.161","article-title":"The biological and clinical behaviour of pilocytic astrocytomas of the optic pathways","volume":"105","author":"Borit","year":"1982","journal-title":"Brain"},{"key":"10.1016\/j.critrevonc.2025.104953_bib9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104953_bib10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma","volume":"30","author":"Bouffet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.42.3.679","article-title":"Spontaneous regression of optic glioma in a patient with neurofibromatosis","volume":"42","author":"Brzowski","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2025.104953_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11060-014-1652-6","article-title":"Single agent vinorelbine in pediatric patients with progressive optic pathway glioma","volume":"121","author":"Cappellano","year":"2015","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0733-8619(18)30297-4","article-title":"Optic pathway tumors","volume":"9","author":"Cohen","year":"1991","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.critrevonc.2025.104953_bib14","first-page":"4","article-title":"Neuro-Oncology practice clinical debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma","volume":"7","author":"Cooney","year":"2020","journal-title":"Neurooncol. Pr."},{"key":"10.1016\/j.critrevonc.2025.104953_bib15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1215\/15228517-2007-031","article-title":"Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program","volume":"9","author":"Dalla Via","year":"2007","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib16","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0404.1999.tb00409.x","article-title":"Malignant optic glioma of adulthood. Case report and review of the literature","volume":"100","author":"Dario","year":"1999","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.critrevonc.2025.104953_bib17","first-page":"1114","article-title":"Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma","volume":"38","author":"Deliganis","year":"1996","journal-title":"Neurosurgery"},{"key":"10.1016\/j.critrevonc.2025.104953_bib18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0002-9394(79)90080-1","article-title":"Optic chiasmatic glioma in children","volume":"87","author":"DeSousa","year":"1979","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib19","first-page":"68","article-title":"Development of anaplastic changes in low-grade astrocytomas of childhood","volume":"34","author":"Dirks","year":"1994","journal-title":"Neurosurgery"},{"key":"10.1016\/j.critrevonc.2025.104953_bib20","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a pediatric brain tumor consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3171\/jns.1986.65.2.0154","article-title":"Chiasmal gliomas: appearance and long-term changes demonstrated by computerized tomography","volume":"65","author":"Fletcher","year":"1986","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/1097-0142(19880215)61:4<635::AID-CNCR2820610403>3.0.CO;2-2","article-title":"Management of low-grade gliomas of the optic nerve and chiasm","volume":"61","author":"Flickinger","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib24","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/bjo.57.10.788","article-title":"Glioblastoma of the optic chiasm","volume":"57","author":"Gibberd","year":"1973","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1531-8249(199903)45:3<393::AID-ANA17>3.0.CO;2-B","article-title":"Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma","volume":"45","author":"Grill","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<166::AID-CNCR22>3.0.CO;2-U","article-title":"Treatment of diencephalic syndrome with chemotherapy: growth, tumor response, and long term control","volume":"83","author":"Gropman","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-3476(95)70449-3","article-title":"Precocious puberty in children with neurofibromatosis type 1","volume":"126","author":"Habiby","year":"1995","journal-title":"J. Pedia"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104953_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjo.57.4.253","article-title":"Malignant optic nerve glioma. Report of a case with electron microscope study","volume":"57","author":"Hamilton","year":"1973","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib29","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/cncr.33497","article-title":"Early radiotherapy preserves vision in sporadic optic pathway glioma","volume":"127","author":"Hanania","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000120729","article-title":"Optic pathway\/hypothalamic gliomas: a dilemma in management","volume":"19","author":"Hoffman","year":"1993","journal-title":"Pedia Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/brain\/96.1.121","article-title":"Malignant optic glioma of adulthood","volume":"96","author":"Hoyt","year":"1973","journal-title":"Brain"},{"key":"10.1016\/j.critrevonc.2025.104953_bib32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/pbc.24297","article-title":"Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas","volume":"60","author":"Hwang","year":"2013","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0002-9394(14)76780-7","article-title":"Magnetic resonance imaging signs of optic nerve gliomas in neurofibromatosis 1","volume":"111","author":"Imes","year":"1991","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/sj.bjc.6605179","article-title":"Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours","volume":"101","author":"Jacob","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0161-6420(84)34316-0","article-title":"Combined clinical and computed tomographic diagnosis of orbital glioma and meningioma","volume":"91","author":"Jakobiec","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.critrevonc.2025.104953_bib36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/1097-0142(19950215)75:4<1051::AID-CNCR2820750423>3.0.CO;2-S","article-title":"Optic pathway and hypothalamic\/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up","volume":"75","author":"Janss","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib37","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/neuonc\/not120","article-title":"Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1","volume":"15","author":"Kelly","year":"2013","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archneur.1981.00510030090015","article-title":"AJ. Progressive visual loss due to glioblastoma: normal neuroroentgenorgraphic studies","volume":"38","author":"Kennerdell","year":"1981","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3171\/jns.1993.79.1.0032","article-title":"Moyamoya phenomenon after radiation for optic glioma","volume":"79","author":"Kestle","year":"1993","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104953_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3928\/0191-3913-19820101-06","article-title":"Optic glioma masquerading as spasmus nutans","volume":"19","author":"Koenig","year":"1982","journal-title":"J. Pedia Ophthalmol. Strabismus"},{"key":"10.1016\/j.critrevonc.2025.104953_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01405505","article-title":"Surgery of giant gliomas of chiasma and IIIrd ventricle","volume":"130","author":"Konovalov","year":"1994","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.critrevonc.2025.104953_bib43","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/neuonc\/noac013","article-title":"Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1","volume":"24","author":"Kotch","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib44","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0360-3016(90)90418-J","article-title":"Radiation therapy for gliomas of the optic nerve and chiasm","volume":"18","author":"Kovalic","year":"1990","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104953_bib45","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2003.03.043","article-title":"Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French society of pediatric oncology","volume":"21","author":"Laithier","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for Chemotherapy-Na\u00efve children with progressive Low-Grade glioma: a Canadian pediatric brain tumor consortium study","author":"Lassaletta","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/59.9.759","article-title":"Loss of neurofibromin is associated with activation of RAS\/MAPK and PI3-K\/AKT signaling in a neurofibromatosis 1 astrocytoma","volume":"59","author":"Lau","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0161-6420(84)34269-5","article-title":"Acquired nystagmus in early childhood: a presenting sign of intracranial tumor","volume":"91","author":"Lavery","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.critrevonc.2025.104953_bib49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3476(89)80137-4","article-title":"Optic gliomas in children with neurofibromatosis type 1","volume":"114","author":"Listernick","year":"1989","journal-title":"J. Pedia"},{"key":"10.1016\/j.critrevonc.2025.104953_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3476(94)70122-9","article-title":"Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study","volume":"125","author":"Listernick","year":"1994","journal-title":"J. Pedia"},{"key":"10.1016\/j.critrevonc.2025.104953_bib51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M","article-title":"Intracranial gliomas in neurofibromatosis type 1","volume":"89","author":"Listernick","year":"1999","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.critrevonc.2025.104953_bib52","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0022-3476(95)70159-1","article-title":"Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history","volume":"127","author":"Listernick","year":"1995","journal-title":"J. Pedia"},{"key":"10.1016\/j.critrevonc.2025.104953_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ana.410410204","article-title":"Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task force","volume":"41","author":"Listernick","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib55","article-title":"Epidemiology and survival of patients with optic pathway gliomas: a Population-Based analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib56","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1212\/WNL.46.6.1669","article-title":"Gangliogliomas involving the optic chiasm","volume":"46","author":"Liu","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2025.104953_bib57","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/neuonc\/noac241","article-title":"The clinical and molecular characteristics of progressive hypothalamic\/optic pathway pilocytic astrocytoma","volume":"25","author":"Li","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib58","series-title":"WHO Classification of Tumours of the Central Nervous System","author":"Louis","year":"2016"},{"key":"10.1016\/j.critrevonc.2025.104953_bib59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00247-021-05226-1","article-title":"Non-inferiority of a non-gadolinium-enhanced magnetic resonance imaging follow-up protocol for isolated optic pathway gliomas","volume":"52","author":"Maloney","year":"2022","journal-title":"Pedia Radio."},{"key":"10.1016\/j.critrevonc.2025.104953_bib60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2016.9.PEDS16328","article-title":"Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response","volume":"19","author":"Miller","year":"2017","journal-title":"J. Neurosurg. Pedia"},{"key":"10.1016\/j.critrevonc.2025.104953_bib61","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/brain\/97.1.743","article-title":"Evaluation and management of gliomas of the anterior visual pathways","volume":"97","author":"Miller","year":"1974","journal-title":"Brain"},{"key":"10.1016\/j.critrevonc.2025.104953_bib62","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.ejca.2010.03.028","article-title":"Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence","volume":"46","author":"Moreno","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib63","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/jjco\/hyt124","article-title":"Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent\/refractory solid tumors","volume":"43","author":"Okada","year":"2013","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib64","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","article-title":"Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas","volume":"86","author":"Packer","year":"1997","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib65","first-page":"212","article-title":"Intracranial visual pathway gliomas in children with neurofibromatosis","volume":"1","author":"Packer","year":"1988","journal-title":"Neurofibromatosis"},{"key":"10.1016\/j.critrevonc.2025.104953_bib66","first-page":"393","article-title":"Chiasmatic gliomas of childhood. A reappraisal of natural history and effectiveness of cranial irradiation","volume":"10","author":"Packer","year":"1983","journal-title":"Childs Brain"},{"key":"10.1016\/j.critrevonc.2025.104953_bib67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.410230113","article-title":"Treatment of chiasmatic\/hypothalamic gliomas of childhood with chemotherapy: an update","volume":"23","author":"Packer","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib68","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/088307389901400602","article-title":"Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility","volume":"14","author":"Perilongo","year":"1999","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/1097-0142(19900101)65:1<45::AID-CNCR2820650111>3.0.CO;2-Z","article-title":"Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects","volume":"65","author":"Pierce","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib70","first-page":"467","article-title":"Childhood moyamoya syndrome. Postradiation pathogenesis","volume":"5","author":"Rajakulasingam","year":"1979","journal-title":"Childs Brain"},{"key":"10.1016\/j.critrevonc.2025.104953_bib71","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/NEN.0b013e3182656ef8","article-title":"BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper","volume":"71","author":"Rodriguez","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib72","first-page":"238","article-title":"Malignant optic nerve gliomas in adults","volume":"5","author":"Rudd","year":"1985","journal-title":"J. Clin. Neuroophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib73","first-page":"1213","article-title":"Optic glioma","volume":"89","author":"Rush","year":"1982","journal-title":"Long. Term. Follow 85 Histopathol. Verif. cases. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000120335","article-title":"Pediatric diencephalic gliomas--a review of 18 cases","volume":"13","author":"Scott","year":"1987","journal-title":"Pedia Neurosci."},{"key":"10.1016\/j.critrevonc.2025.104953_bib75","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1200\/JCO.2005.03.8349","article-title":"Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy","volume":"24","author":"Sharif","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/adc.76.3.259","article-title":"Visual pathway glioma: an erratic tumour with therapeutic dilemmas","volume":"76","author":"Shuper","year":"1997","journal-title":"Arch. Dis. Child"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104953_bib77","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-24-3439","article-title":"FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma","volume":"31","author":"Singh","year":"2025","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104953_bib78","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0002-9394(80)90126-9","article-title":"Malignant gliomas of the optic nerve pathways","volume":"89","author":"Spoor","year":"1980","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib79","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3171\/jns.1995.83.4.0583","article-title":"Long-term outcome of hypothalamic\/chiasmatic astrocytomas in children treated with conservative surgery","volume":"83","author":"Sutton","year":"1995","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib80","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1227\/00006123-198308000-00003","article-title":"Cerebral gangliogliomas during childhood","volume":"13","author":"Sutton","year":"1983","journal-title":"Neurosurgery"},{"key":"10.1016\/j.critrevonc.2025.104953_bib81","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0360-3016(97)00359-3","article-title":"Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome","volume":"39","author":"Tao","year":"1997","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104953_bib82","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3171\/jns.1989.70.2.0277","article-title":"Malignant optic glioma in adults. Case report","volume":"70","author":"Taphoorn","year":"1989","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib83","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1259\/bjr\/65246351","article-title":"Radiological classification of optic pathway gliomas: experience of a modified functional classification system","volume":"81","author":"Taylor","year":"2008","journal-title":"Br. J. Radio."},{"key":"10.1016\/j.critrevonc.2025.104953_bib84","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3171\/jns.1982.57.4.0452","article-title":"The neurosurgical management of optic glioma. Results in 104 patients","volume":"57","author":"Tenny","year":"1982","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib85","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12885-024-11820-x","article-title":"LOGGIC\/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. Chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration","volume":"24","author":"van Tilburg","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104953_bib86","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1212\/01.wnl.0000257095.33125.48","article-title":"Moyamoya following cranial irradiation for primary brain tumors in children","volume":"68","author":"Ullrich","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2025.104953_bib87","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00381-018-3739-4","article-title":"Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases","volume":"34","author":"Upadhyaya","year":"2018","journal-title":"Childs Nerv. Syst."},{"key":"10.1016\/j.critrevonc.2025.104953_bib88","unstructured":"US Food and Drug Administration, FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric\u3009, 2024 (accessed 13 June 2024)."},{"key":"10.1016\/j.critrevonc.2025.104953_bib89","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/02688690601101382","article-title":"Multiple gangliogliomas of the optic pathway","volume":"20","author":"Vajramani","year":"2006","journal-title":"Br. J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib90","first-page":"421","article-title":"Postoperative regression of opticochiasmatic astrocytoma: a case for expectant therapy","volume":"15","author":"Venes","year":"1984","journal-title":"Neurosurgery"},{"key":"10.1016\/j.critrevonc.2025.104953_bib91","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-016-2163-4","article-title":"Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1","volume":"129","author":"Wan","year":"2016","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.critrevonc.2025.104953_bib92","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.22.01777","article-title":"Phase II randomized trial of lenalidomide in children with pilocytic astrocytomas and optic pathway gliomas: a report from the children's oncology group","volume":"41","author":"Warren","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib93","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00401-002-0580-2","article-title":"Anaplastic progression in low grade glioneural neoplasms","volume":"104","author":"Whittle","year":"2002","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2025.104953_bib94","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3171\/jns.1990.73.5.0661","article-title":"Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood","volume":"73","author":"Wisoff","year":"1990","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104953_bib95","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00381-019-04407-6","article-title":"Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review","volume":"36","author":"Yamasaki","year":"2020","journal-title":"Childs Nerv. Syst."},{"key":"10.1016\/j.critrevonc.2025.104953_bib96","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e3181c0664a","article-title":"Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma","volume":"73","author":"Yu","year":"2009","journal-title":"Neurology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:15:58Z","timestamp":1767388558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":96,"alternative-id":["S1040842825003415"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104953","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding optic pathway gliomas: Molecular insights and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104953"}}